Piramal Pharma Greenlights $90 Million Global Expansion: Lexington Facility at the Heart of Growth Push

Unknown Apr 02, 2026 950 Views

Piramal Pharma Ltd’s Board of Directors has given the green light to an ambitious expansion plan of up to $90 million, with a major focus on scaling its Lexington, Kentucky facility in the United States. This strategic investment underscores Piramal Pharma’s commitment to strengthenin...

Key Highlights:

Major Investment in the U.S.: The company will invest $80 million in expanding its Lexington, Kentucky site, adding 24,000 sq ft of manufacturing space, a new laboratory, and advanced machinery. This will more than double the facility’s capacity from 104 to over 240 product batches annually by Q1 2027, meeting surging demand in the injectables market.
Driving Innovation in Injectables: The Lexington site specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drugs. The expansion will support Piramal’s integrated antibody-drug-conjugate (ADC) program and attract new client commitments for commercializing products at the site.
Job Creation & Economic Impact: The project will create over 40 full-time jobs in Kentucky, boosting the local economy while enhancing Piramal’s global manufacturing footprint.
Funding and Strategy: The expansion will be financed through a mix of bank loans and internal accruals, reflecting the company’s financial discipline and long-term vision.
Market Opportunity: The global injectables market is projected to surpass $20 billion by 2028, and Piramal’s expansion positions it to capture a significant share of this rapidly growing segment.
Leadership Commentary: Chairperson Nandini Piramal highlighted the move as a strategic investment that fills a critical commercial manufacturing gap and reinforces Piramal’s reputation as a reliable partner for biologics and complex generics.